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Background: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is 
limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins 
affected renal function in Asian patients with diabetes.
Methods: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treat-
ed with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome 
was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was de-
fined as a >3% reduction in eGFR in a 1-year period.
Results: In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 
to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid 
eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic 
regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjust-
ment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42).
Conclusion: These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than 
that of rosuvastatin.
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INTRODUCTION
The prevalence and incidence of chronic kidney disease (CKD) 
have been increasing, and CKD is recognized as an epidemic 
disease [1]. The leading cause of CKD is diabetes mellitus (DM) 
[2,3]; it starts as diabetic nephropathy and progresses to CKD 
[4]. In addition to hyperglycemia, dyslipidemia is an important 
risk factor for renal function loss [5,6]. When DM and dyslipid-
emia co-occur, the risk of CKD is synergistically increased [2,7]. 
Conversely, CKD itself can accelerate lipid concentrations, ag-
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gravating dyslipidemia [8] and leading to the need for more treat-
ment [9]. 
The 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
hibitors, referred to as statins, are the fundamental treatment for 
dyslipidemia, and they decrease the risk of cardiovascular mor-
bidity and mortality [10]. Basic research studies have shown that 
statins also have the potential to protect the kidney via anti-in-
flammatory and anti-proliferative pathways [11]. However, the 
effect of statins on kidney function in the clinic is controversial. 
The Collaborative Atorvastatin Diabetes Study provided evidence 
that atorvastatin treatment has beneficial effects on the kidney 
compared with those of placebo treatment [12]. In contrast, an-
other study showed that more subjects in a high-intensity dose 
rosuvastatin (40 mg/day) treatment group experienced new-on-
set proteinuria than in a placebo group; although, rosuvastatin 
treatment attenuated atherosclerosis progression [13]. A meta-
analysis study reported similar renoprotective effects between 
atorvastatin and rosuvastatin treatment groups [14]. However, 
recently, a randomized clinical trial using high-intensity dose 
rosuvastatin (40 mg/day) and atorvastatin (80 mg/day) treatments 
showed that atorvastatin has more beneficial effects on the kid-
ney than those of rosuvastatin [5].
Previous studies on statins were based largely on Caucasian 
populations and conducted using high-intensity doses [5,13]. 
However, interestingly, one study showed a comparable lipid 
lowering efficacy using lower statin doses in Asians with that 
observed using higher doses in Caucasians [15]. Therefore, the 
aim of this study was to investigate and compare the renal ef-
fects of moderate-intensity doses of statins in Asian patients 
with diabetes.
 
METHODS
Study design and population
In this study, subjects were identified by reviewing patient case 
notes using the electronic medical records at Severance Hospi-
tal, a tertiary university hospital in Korea. We initially selected 
those aged ≥20 years who were naïve, and started moderate-in-
tensity statin treatment. DM was defined according to the Inter-
national Classification of Diseases 10th revision (ICD-10). Sub-
jects were excluded if they had any one of the following criteria: 
(1) missing data for laboratory tests; (2) <12 months of statin 
treatment; (3) prior kidney transplantation or ongoing dialysis; 
(4) kidney disease other than diabetic nephropathy (nephritis or 
nephrotic syndrome); (5) acute renal failure due to septic shock, 
contrast agents, or drugs; (6) DM developed after statin use; or 
(7) post-transplant DM with immunosuppressant medication 
treatment. The study protocol was approved by the Institutional 
Review Board of the Yonsei University College of Medicine (4-
2016-0741).
Clinical and laboratory parameters
Clinical parameters, including age, sex, height, weight, duration 
of DM, history of hypertension and cardiac disease, and statin 
treatment information, were collected by carefully reviewing 
electronic medical records. Fasting blood glucose levels, glycat-
ed hemoglobin (HbA1c) levels, lipid profiles (total cholesterol, 
low density lipoprotein cholesterol [LDL-C], high density lipo-
protein cholesterol [HDL-C], and triglyceride levels), and esti-
mated glomerular filtration rates (eGFR) were measured at base-
line and 12 months after statin administration. The eGFR was 
calculated using the Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equation, and the CKD stages were cate-
gorized according to previously described guidelines [16]. In 
addition, the proportion of subjects with rapid renal function de-
cline was analyzed by statin types and was defined as those ex-
hibiting a >3% loss in annual eGFR [17]. Body mass index 
(BMI) was evaluated using a weight-to-height (kg/m2) ratio, and 
obesity was defined as a BMI ≥25 kg/m2 based on the criteria for 
Asians.
Statistical analysis
Data are presented as the mean±standard deviation for continu-
ous variables and as a number or percentage for categorical vari-
ables. Simple comparisons of continuous variables between statin 
types were analyzed using Student t tests. Paired data measured 
at baseline and after statin treatment were analyzed using paired 
t tests. Because total cholesterol, triglyceride, HDL-C, LDL-C, 
aspartate aminotransferase, and alanine transaminase values were 
not normally distributed, analyses were performed using log-
transformed data. Chi-square tests were used to examine the re-
lationships between multiple categorical variables. The relative 
factor for rapid renal function decline was obtained using multi-
variable logistic regression models, and the risk is reported in 
the form of odds ratios (ORs) and 95% confidence intervals (CIs). 
In multivariable logistic regression analysis, age, sex, diabetes 
duration, angiotensin-converting enzyme (ACE) inhibitor/an-
giotensin receptor blocker (ARB) use, systolic blood pressure, 
hypertension status, baseline eGFR, LDL-C, triglyceride, and 
HbA1c concentration changes during follow-up periods were 
adjusted as covariates. Statistical analyses were performed us-
ing IBM SPSS version 23.0 (IBM Corp., Armonk, NY, USA). 
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Table 1. Baseline Characteristics of Study Population by Categories of Statin Types
Characteristic Atorvastatin (n=295) Rosuvastatin (n=189) P value
Age, yr 61.3±11.3 59.7±11.8 0.141
Male sex 152 (51.5) 114 (60.3) 0.058a
Diabetes duration, yr 9.3±9.6 8.6±9.0 0.365
BMI, kg/m2 25.0±3.9 25.3±3.7 0.373
Obesity 125 (45.1) 76 (50.0) 0.333a
SBP, mm Hg 127.8±15.6 129.3±16.7 0.337
DBP, mm Hg 75.4±11.9 76.9±10.9 0.177
FBS, mg/dL 148.5±54.5 150.2±56.3 0.742
PPBS, mg/dL 240.1±88.7 255.2±86.7 0.150
HbA1c, % 7.8±1.6 8.1±1.9 0.053
TC, mg/dLb 191.4±47.6 194.2±49.6 0.826
HDL-C, mg/dLb 46.0±11.6 44.0±9.8 0.058
TG, mg/dLb 151.9±96.3 172.6±114.2 0.002
LDL-C, mg/dLb 115.3±39.4 116.0±44.4 0.684
BUN, mg/dL 18.8±10.5 18.7±8.8 0.882
Cr, mg/dL 1.0±0.7 1.0±0.5 0.999
eGFR, mL/min/1.73 m2c 80.3±26.4 79.1±25.6 0.633
CKD stage
   Stage 1
   Stage 2
   Stage 3–5
143 (48.5)
86 (29.2)
66 (22.4)
84 (44.4)
58 (30.7)
47 (24.9)
0.671a
WBC, 103/μL 7.0±1.9 7.3±2.1 0.227
Hemoglobin, mg/dL 13.4±1.9 13.4±2.0 0.943
Albumin, mg/dL 4.5±2.6 4.4±1.9 0.595
AST, U/Lb 23.1±13.2 24.2±20.7 0.455
ALT, U/Lb 25.0±15.7 26.8±20.1 0.319
Comorbidities
   Cardiac disorders 
   Hypertension
73 (24.7)
137 (46.4)
49 (25.9)
101 (53.4)
0.770a
0.133a
Antihypertensive medications
   ACE inhibitor or ARB
   Diuretics
   CCB
   β-Blocker
151 (51.2)
55 (18.6)
86 (29.2)
46 (15.6)
108 (57.1)
36 (19.1)
65 (34.4)
37 (19.6)
0.200a
0.890a
0.225a
0.257a
Glucose lowering medications
   Metformin
   Sulfonylurea
   DPP-4 inhibitor
   TZD
   Insulin
238 (80.7)
124 (42.0)
129 (43.7)
35 (11.9)
63 (21.4)
153 (81.0)
71 (37.6)
75 (39.7)
17 (9.0)
40 (21.2)
0.940a
0.328a
0.379a
0.320a
0.960a
Values are expressed as mean±SD or number (%).
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, fasting blood sugar; PPBS, postprandial blood sugar; HbA1c, 
glycated hemoglobin; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; 
BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; WBC, white blood cell; AST, aspartate aminotrans-
ferase; ALT, alanine transaminase; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DPP-4, 
dipeptidyl peptidase-4; TZD, thiazolidinedione.
aAnalyzed by chi-square test; bLog-transformed; ceGFR was calculated from Chronic Kidney Disease Epidemiology Collaboration.
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For all tests, a P<0.05 was considered to be statistically signifi-
cant.
RESULTS
In this study, we analyzed 484 individuals undergoing moder-
ate-intensity statin treatment. The mean age of the study popula-
tion was 60.7 years, and the mean duration of DM was 9.0 years. 
Of the 484 patients, 266 (55.0%) were men, 238 (49.2%) had 
hypertension, and 259 (53.5%) were prescribed an ACE inhibi-
tor or an ARB. The mean daily dosage was 11.2±3.2 mg for 
atorvastatin (88.1% had 10 mg/day, 11.9% had 20 mg/day) and 
9.7±1.3 mg for rosuvastatin (6.9% had 5 mg/day, 93.1% had 10 
mg/day). There were no significant differences between the statin 
groups in age, DM duration, BMI, blood pressure, blood glu-
cose levels, or liver and kidney function (Table 1). In addition, 
the prevalence of cardiac disorders and hypertension, the class 
of antihypertensive drug, and the use of hypoglycemic medica-
tion, were comparable between the two groups. 
Among all patients, the eGFR was slightly, but significantly, 
decreased from 79.8 to 77.7 mL/min/1.73 m2 (P<0.001). The 
mean eGFR change was similar as previously reported in diabetes 
population [18,19]. Although this renal function decline was ob-
served in both statin treatment groups, there was a greater eGFR re-
duction in the rosuvastatin-treated group (Δ-1.6 mL/min/1.73 m2 
for atorvastatin [P=0.012], Δ-3.0 mL/min/1.73 m2 for rosuvas-
tatin [P=0.001]) (Table 2). In addition, more individuals receiv-
ing rosuvastatin treatment experienced rapid renal function de-
cline than those receiving atorvastatin treatment (48.7% vs. 
38.6%, P=0.029).
Serum lipid profiles and blood glucose levels were significant-
ly improved in both study groups (Table 2). The mean reduc-
tions in total cholesterol, LDL-C, and triglyceride levels were 
19.9%, 27.1%, and 5.4%, respectively, after 1 year of statin treat-
ment (all P<0.001), whereas HDL-C levels were slightly in-
creased by 2.7% (P=0.527). The proportion of individuals who 
achieved an LDL-C response (>30% reduction) was similar be-
tween the statin groups (52.2% and 59.6% for atorvastatin and 
rosuvastatin, respectively, P=0.115). Total cholesterol and tri-
glyceride levels were also improved regardless of statin treat-
ment; however, neither statin treatment significantly increased 
or decreased HDL-C levels. 
Next, we assessed rapid renal function decline according to 
statin type after adjusting for confounding factors, including age, 
sex, and other clinical and laboratory parameters. As the atorvas-
tatin-treated group showed a better response in terms of kidney 
function maintenance, we set this group as the reference. Multi-
variable logistic regression analysis showed that rosuvastatin 
treatment was independently associated with rapid renal func-
tion decline (Table 3). Compared with atorvastatin treatment, ro-
suvastatin treatment increased the risk for rapid renal function 
loss by approximately 60% (OR, 1.60; 95% CI, 1.06 to 2.42). 
Table 2. Changes in Metabolic Parameters after Statin Use
Parameter
Atorvastatin Rosuvastatin
Baseline 1 Year P value Baseline 1 Year P value
Kidney
   eGFR, mL/min/1.73 m2 80.3±26.4 78.7±27.5 0.012 79.1±25.6 76.1±26.8 0.001
Lipid
   TC, mg/dLa 191.4±47.6 149.7±33.5 <0.001 194.2±49.6 142.1±33.0 <0.001
   HDL-C, mg/dLa 46.0±11.6 45.5±11.8 0.068 44.0±9.8 45.7±12.7 0.060
   TG, mg/dLa 151.9±96.3 130.9±79.3 0.001 172.6±114.2 131.2±68.8 <0.001
   LDL-C, mg/dLa 115.3±39.4 78.1±24.1 <0.001 116.0±44.4 70.4±28.6 <0.001
Glucose
   FBS, mg/dL 148.5±54.5 128.7±36.0 <0.001 150.2±56.3 131.4±40.3 <0.001
   PPBS, mg/dL 240.1±88.7 220.6±77.0 <0.001 255.2±86.7 213.9±67.6 <0.001
   HbA1c, % 7.8±1.6 7.2±1.1 <0.001 8.1±1.9 7.4±1.5 <0.001
Values are expressed as mean±SD. 
GFR, glomerular filtration rate; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cho-
lesterol; FBS, fasting blood sugar; PPBS, postprandial blood sugar; HbA1c, glycated hemoglobin.
aLog-transformed.
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DISCUSSION
Because of the suggested similarity in pathophysiology between 
atherosclerosis and glomerulosclerosis [20], the association be-
tween hyperlipidemia and kidney disease progression has been 
explored in experimental studies. High-fat diet induces aggrava-
tion in glomerulosclerosis, accumulation of mesangial matrix, 
and podocyte injury [21,22]. Conversely, statin treatment decre-
ases macrophage recruitment and reduces the levels of inflam-
matory cytokines, including monocyte chemoattractant protein-1, 
transforming growth factor β, and interleukin 6; thereby, attenu-
ating renal fibrosis [23-25]. Although there is some debate re-
garding the effect of statin treatment on kidney function in hu-
mans, there is increasing evidence that statins have a renopro-
tective effect [25-27]. A large, population-based retrospective 
cohort study reported that preoperative statin use is associated 
with a lower incidence of acute kidney injury and acute dialysis 
after major elective surgery [26]. Additionally, statin use is as-
sociated with an early recovery of kidney injury and a reduced 
risk of all-cause mortality after vascular surgery [27]. A meta-
analysis study also reported favorable changes in GFR, albumin-
uria, and proteinuria in patients treated with statins [28]. 
However, renal outcome according to statin potency is more 
controversial. A Canadian group reported a dose-dependent favor-
able effect of statin treatment, with 37% of the patients undergo-
ing a high-potency statin treatment [26]. Similarly, another study 
showed that high-dose atorvastatin (80 mg/day) improves renal 
outcome compared with that of the low-dose group (10 mg/day) 
[29]. In contrast, a recent large epidemiology study showed an 
increased risk of hospitalization for acute kidney injury in pa-
tients receiving high-potency statin treatment compared with 
those receiving low-potency statin treatment [30]. Moreover, a 
meta-analysis study also reported that high-dose rosuvastatin 
(40 mg/day) causes a higher new-onset proteinuria incidence 
than low-dose rosuvastatin [13]. 
Regarding statin types and renal function, atorvastatin seems 
to be more beneficial than rosuvastatin [5,13]. In a previous ran-
domized control trial, the rosuvastatin group showed greater re-
ductions in lipid profiles, and concomitantly showed significant 
reductions in the GFRs and more acute renal failure events, com-
pared with those in the atorvastatin group [5]. In another study, 
the GFR reduction was less in the atorvastatin-treated group than 
in the rosuvastatin-treated group [13]. These data are consistent 
with our results and support the notion that a more rapid GFR 
loss is associated with rosuvastatin use than with atorvastatin 
use. However, previous studies were mainly conducted in Cau-
casians and did not include Asian populations [5,12,13]. Our 
study supports the notion that the beneficial effects of atorvas-
tatin treatment in Asians are not different from those previously 
observed in Caucasians [5,13], and that these effects are main-
tained using moderate-intensity doses.
Although the differences between the mechanisms of atorvas-
tatin and rosuvastatin in kidney function remains unknown, the 
following observations regarding these drugs may contribute to 
their unique renal effects. One retrospective study demonstrated 
a greater decrease in serum uric acid levels with atorvastatin treat-
ment than with rosuvastatin treatment, which could lead to in-
creased endothelial function and renal blood flow [31]. Even 
though we did not observe a significant difference between the 
serum uric acid levels in the two statin treatment groups in the 
current study, both statin treatments did reduce patient serum uric 
acid levels. In addition, X-ray diffraction analyses have shown 
various distributions of each statin class in the cellular membrane, 
which are associated with the metabolites of each statin, and this 
altered distribution could affect the pharmacologic and pleiotro-
pic properties of the statins [32]. For instance, this altered distri-
bution might influence intracellular signaling in the kidney, which 
could explain the observed decrease in urinary podocyte excre-
tion in patients that were switched to atorvastatin treatment from 
rosuvastatin treatment for a 6-month period [33]. We analyzed 
the correlation between changes in eGFR and LDL-C reduction, 
found no statistical significance in the current study (Pearson 
coefficient=0.08, P=0.08). This might be due to the difference 
effect of atorvastatin and rosuvastatin. Further studies are neces-
sary to elucidate the downstream mediators of the distinct renal 
effects of these two statins. 
Our study has some limitations. First, this was a retrospective 
Table 3. Odds Ratio and 95% Confidence Interval of Rapid Re-
nal Function Decline (>3% per Year) According to Statin Types
Variable Atorvastatin Rosuvastatin P value
Crude 1 (reference) 1.51 (1.04–2.18) 0.030
Model 1a 1 (reference) 1.48 (1.01–2.15) 0.042
Model 2b 1 (reference) 1.48 (1.00–2.20) 0.052
Model 3c 1 (reference) 1.60 (1.06–2.42) 0.026
aModel 1: adjusted for age and sex; bModel 2: adjusted for age, sex, dia-
betes duration, angiotensin-converting enzyme (ACE) inhibitor/angio-
tensin receptor blocker (ARB) use, systolic blood pressure, and hyper-
tension; cModel 3: adjusted for age, sex, diabetes duration, ACE inhibi-
tor/ARB use, systolic blood pressure, hypertension, baseline glomerular 
filtration rate, low density lipoprotein cholesterol change, triglyceride 
change, and glycated hemoglobin change.
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investigation, and thus, causal relationships cannot be clearly 
deducted. Second, although there were no differences in medi-
cation use, including ACE inhibitors and ARB, among the statin 
groups, and we accounted for the differences in glucose and lip-
id levels at baseline and 12 months after statin treatment, the 
changes in blood glucose and blood pressure during the treat-
ment period could not be determined. Third, we did not include 
a control group in the present study; therefore, no definitive con-
clusions can be drawn regarding which statin is more harmful, 
neutral, or protective. Fourth, as shown in Table 1, more indi-
viduals with impaired baseline metabolic parameters were in-
cluded in the rosuvastatin group. Although we adjusted for chan-
ges in glucose and lipid levels in the multivariable model, this 
discrepancy could be a confounding factor. Finally, we applied 
GFR-EPI equation as renal function in the current study, which 
is indirect renal function.
Despite these limitations, the present study has several strengths. 
To the best of our knowledge, this study is the first to show that 
moderate-intensity statin treatment in Asians, who are known to 
respond well to lower statin doses, exerted beneficial effects to 
maintain kidney function. Although this study was retrospective, 
which is not suitable to precisely determine patient compliance, 
we limited enrollment to patients whose prescriptions consis-
tently included the same statins by careful reviewing their medi-
cal records. In addition, patients with other kidney disease, such 
as nephritis or nephrotic syndrome, were excluded to specifical-
ly evaluate the effects of statins on urinary kidney disease and 
diabetic nephropathy.
In conclusion, moderate-intensity dose statin treatment for 12 
months significantly improved LDL-C and triglyceride levels in 
patients with diabetes. We found that moderate-intensity dose 
rosuvastatin treatment was associated with more rapid GFR loss 
than that of atorvastatin treatment. Our findings suggest that ator-
vastatin treatment in diabetic patients is more beneficial in pre-
serving the GFR than rosuvastatin treatment. However, further 
prospective and randomized trials are needed to verify this ef-
fect compared with placebo and other statin treatments. If the 
class effects of statins on diabetic nephropathy are clearly dem-
onstrated, the options for treating diabetic patients with statins 
will be vastly improved.
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